Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Champlin

Showing results (171-180 of 768) with videos related to

Pageof 77
Sort By:
Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists|September 22, 2009
Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects designMelissa A Friedman, Mercedes Fernandez, Jeffrey S Wefel, et al.
Leukemia & Lymphoma|October 26, 2011
Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell linesBenigno C Valdez, David Murray, Yago Nieto, et al.
The American Journal of Medicine|March 30, 1984
Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. Preliminary results of a controlled trialD J Winston, W G Ho, C H Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1992
Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remissionG J Schiller, S D Nimer, M C Territo, et al.
Leukemia & Lymphoma|October 23, 2013
The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfanGuiyun Song, Benigno C Valdez, Yang Li, et al.
Bone Marrow Transplantation|July 3, 2007
Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantationE Jabbour, G Rondon, P Anderlini, et al.
Cancer|January 11, 2005
The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantationAmar Safdar, Gilhen Rodriguez, Norio Ohmagari, et al.
Statistics in Medicine|February 15, 2003
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypesPeter F Thall, J Kyle Wathen, B Nebiyou Bekele, et al.
Plos One|March 8, 2013
Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trialsBipulendu Jena, Sourindra Maiti, Helen Huls, et al.
The American Journal of Medicine|September 1, 1984
Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patientsD J Winston, R C Barnes, W G Ho, et al.
Pageof 77

Showing results (171-180 of 768) with videos related to

Sort By:
Pageof 77
Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists|September 22, 2009
Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects designMelissa A Friedman, Mercedes Fernandez, Jeffrey S Wefel, et al.
Leukemia & Lymphoma|October 26, 2011
Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell linesBenigno C Valdez, David Murray, Yago Nieto, et al.
The American Journal of Medicine|March 30, 1984
Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. Preliminary results of a controlled trialD J Winston, W G Ho, C H Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1992
Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remissionG J Schiller, S D Nimer, M C Territo, et al.
Leukemia & Lymphoma|October 23, 2013
The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfanGuiyun Song, Benigno C Valdez, Yang Li, et al.
Bone Marrow Transplantation|July 3, 2007
Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantationE Jabbour, G Rondon, P Anderlini, et al.
Cancer|January 11, 2005
The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantationAmar Safdar, Gilhen Rodriguez, Norio Ohmagari, et al.
Statistics in Medicine|February 15, 2003
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypesPeter F Thall, J Kyle Wathen, B Nebiyou Bekele, et al.
Plos One|March 8, 2013
Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trialsBipulendu Jena, Sourindra Maiti, Helen Huls, et al.
The American Journal of Medicine|September 1, 1984
Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patientsD J Winston, R C Barnes, W G Ho, et al.
Pageof 77